Label: PROPYLTHIOURACIL tablet

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated October 31, 2021

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION
    Rx only
  • BOXED WARNING (What is this?)

    WARNING

    Severe liver injury and acute liver failure, in some cases fatal, have been reported in patients treated with propylthiouracil. These reports of hepatic reactions include cases requiring liver transplantation in adult and pediatric patients. Propylthiouracil should be reserved for patients who cannot tolerate methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments for the management of hyperthyroidism. Propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy (see WARNINGS and PRECAUTIONS).

    Close
  • DESCRIPTION
    Propylthiouracil, USP is one of the thiocarbamide compounds. It is a white, powdery, crystalline substance that has a bitter taste and is very slightly soluble in water. Propylthiouracil is an ...
  • CLINICAL PHARMACOLOGY
    Propylthiouracil inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodothyronine that are ...
  • INDICATIONS AND USAGE
    Propylthiouracil tablets are indicated: in patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive ...
  • CONTRAINDICATIONS
    Propylthiouracil is contraindicated in patients who have demonstrated hypersensitivity to the drug or any of the other product components.
  • WARNINGS
    Liver Toxicity - Liver injury resulting in liver failure, liver transplantation, or death, has been reported with propylthiouracil therapy in adult and pediatric patients. No cases of liver ...
  • PRECAUTIONS
    General - Patients should be instructed to report any symptoms of hepatic dysfunction (anorexia, pruritus, jaundice, light colored stools, dark urine, right upper quadrant pain, etc.) ...
  • ADVERSE REACTIONS
    The following adverse reactions have been reported with the use of propylthiouracil. Because these events generally come from voluntary reporting from a population of uncertain size, it is not ...
  • OVERDOSAGE
    Signs and Symptoms - Nausea, vomiting, epigastric distress, headache, fever, arthralgia, pruritus, edema, and pancytopenia. Agranulocytosis is the most serious effect. Rarely, exfoliative ...
  • DOSAGE AND ADMINISTRATION
    Propylthiouracil is administered orally. The total daily dosage is usually given in 3 equal doses at approximately 8-hour intervals. Adults - The initial dose is 300 mg daily. In patients with ...
  • HOW SUPPLIED
    Propylthiouracil tablets, USP are available as follows: 50 mg — Each white, round, tablet imprinted with on one side and 348 and partial bisect on the other side contains 50 mg of ...
  • REFERENCE
    International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. 1974; 7; 67-76. Dispense with Medication Guide available at ...
  • Medication Guide
    Dispense with Medication Guide available at: www.tevausa.com/medguides - Propylthiouracil (proe" pil thye" oh ure' a sil) Tablets - Rx only - Read this Medication Guide before you start taking ...
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
    NDC 0228-2348-10 - Propylthiouracil Tablets, USP - 50 mg - PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only - 100 Tablets
  • INGREDIENTS AND APPEARANCE
    Product Information